Mesenchymal stem cell

Stimulating blood vessel formation with magnets

Wednesday, July 21, 2021 - 11:00pm

This was used to treat endothelial cells, stimulating blood vessel formation.

Key Points: 
  • This was used to treat endothelial cells, stimulating blood vessel formation.
  • "We developed a promising cell therapy alternative that can non-invasively stimulate blood vessel formation or regeneration through the application of an external low-intensity magnetic field."
  • These cells can change into different cell types, and also secrete a protein called VEGF-A that stimulates blood vessel formation.
  • Finally, VEGF-A extracts produced by magnet-treated mesenchymal stromal cells on gelatin increased blood vessel formation in a chick embryo, although further research is needed to confirm these results.

Stem cell therapy company Amniotics raises SEK 60 million before deduction of transaction costs, in First North IPO to advance lead candidate PulmoStem™ into clinic

Monday, July 12, 2021 - 7:00am

LUND, Sweden, July 12, 2021 /PRNewswire/ -- Amniotics AB (publ) ("Amniotics" or the "Company"), a stem cell therapy company has raised SEK60 million through its recent listing on Nasdaq First North Growth Market.

Key Points: 
  • LUND, Sweden, July 12, 2021 /PRNewswire/ -- Amniotics AB (publ) ("Amniotics" or the "Company"), a stem cell therapy company has raised SEK60 million through its recent listing on Nasdaq First North Growth Market.
  • The funds will now be deployed to advance the company's preclinical portfolio of cell therapy candidates based on mesenchymal stem cells (MSC) from amniotic fluid.
  • Lead candidate PulmoStem, a first-in-class treatment for pulmonary disease is scheduled to enter the clinic in Q2, 2022.
  • With the proceeds from the IPO, Amniotics has the financial resources required to move our lead candidate PulmoStem into clinical development.

Stem cell therapy company Amniotics raises SEK 60 million before deduction of transaction costs, in First North IPO to advance lead candidate PulmoStem™ into clinic

Monday, July 12, 2021 - 7:00am

LUND, Sweden, July 12, 2021 /PRNewswire/ -- Amniotics AB (publ) ("Amniotics" or the "Company"), a stem cell therapy company has raised SEK60 million through its recent listing on Nasdaq First North Growth Market.

Key Points: 
  • LUND, Sweden, July 12, 2021 /PRNewswire/ -- Amniotics AB (publ) ("Amniotics" or the "Company"), a stem cell therapy company has raised SEK60 million through its recent listing on Nasdaq First North Growth Market.
  • The funds will now be deployed to advance the company's preclinical portfolio of cell therapy candidates based on mesenchymal stem cells (MSC) from amniotic fluid.
  • Lead candidate PulmoStem, a first-in-class treatment for pulmonary disease is scheduled to enter the clinic in Q2, 2022.
  • With the proceeds from the IPO, Amniotics has the financial resources required to move our lead candidate PulmoStem into clinical development.

FDA Authorizes Simultaneous Stem Cell Trials for Parkinson’s

Monday, June 21, 2021 - 12:00pm

This 60-patient trial is the second FDA clinical trial authorization in Parkinsons for HBSCRF, who already has a 24-patient double-blind placebo trial underway utilizing autologous adipose-derived mesenchymal stem cells.

Key Points: 
  • This 60-patient trial is the second FDA clinical trial authorization in Parkinsons for HBSCRF, who already has a 24-patient double-blind placebo trial underway utilizing autologous adipose-derived mesenchymal stem cells.
  • HBSCRF will become the first research organization in the U.S. to conduct simultaneous trials examining effects of administering the patients own cells (autologous) and donor cells (allogeneic) on the same disease condition.
  • We have to explore every facet of how adipose-derived mesenchymal stem cells act in this disease condition, says HBSCRF Founder Donna Chang.
  • Our primary research focus has always been on autologous stem cells, but in COVID, for example, when we ran three simultaneous studies in prevention and treatment, we encountered a situation where people needed cells but did not have their stem cells banked.

Improved Outcomes in Inflammatory Lung Disease With Remestemcel-L Published in Respiratory Research Journal

Tuesday, May 25, 2021 - 12:00pm

This is the basis for our ongoing investigation of remestemcel-L in the treatment of the severe lung inflammation including ventilator-dependent patients with COVID-19 ARDS.

Key Points: 
  • This is the basis for our ongoing investigation of remestemcel-L in the treatment of the severe lung inflammation including ventilator-dependent patients with COVID-19 ARDS.
  • Remestemcel-L is an investigational therapy comprising culture-expanded mesenchymal stromal cells derived from the bone marrow of an unrelated donor.
  • Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions.
  • Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease and moderate to severe acute respiratory distress syndrome.

Global Cell Therapy Market Report 2021 Featuring Key Innovators Such as JCR Pharmaceuticals, NuVasive, Medipost, Vericel, and Avantor - Market to Reach $28.5 Billion by 2026 - ResearchAndMarkets.com

Thursday, May 20, 2021 - 5:35pm

Allogeneic cell therapy and non-Allogeneic cell therapy.\nAt present, there are two types of cell therapies exist.

Key Points: 
  • Allogeneic cell therapy and non-Allogeneic cell therapy.\nAt present, there are two types of cell therapies exist.
  • This category includes human embryonic stem cell therapy, mesenchymal stem cell therapy, neural stem cell therapy, Autologous cell therapy, and hematopoietic stem cell therapy.
  • The Stem Cell market dominated the Global Cell Therapy Market by Cell Type 2019, and is expected to continue to be a dominant market till 2026.
  • Based on the Analysis presented in the Cardinal matrix; Fujifilm Holdings Corporation is the major forerunner in the Cell Therapy Market.

FDA Approves Orgenesis IDE for Pilot Clinical Trial of its Tissue Genesis Icellator2® to Treat ARDS Resulting from COVID-19 Infection

Thursday, May 6, 2021 - 12:30pm

The SVF derived from the Icellator2 contains a population of mesenchymal stem cells, vascular endothelial cells, and immune cells which migrate to the patient\xe2\x80\x99s lungs and other peripheral sites of inflammation.

Key Points: 
  • The SVF derived from the Icellator2 contains a population of mesenchymal stem cells, vascular endothelial cells, and immune cells which migrate to the patient\xe2\x80\x99s lungs and other peripheral sites of inflammation.
  • Orgenesis believes the multiple mechanisms of action of the SVF derived from the Icellator2 are important to treat ARDS and other inflammatory disorders.\nThe FDA IDE approval covers 21 patients at one clinical site in the United States.
  • We are excited to move forward with clinical development of the Icellator to treat ARDS, COVID-19-related complications, and other serious conditions.
  • Our interactions with the FDA through the IDE process will inform our development plans.

Longeveron Invited to Present at the Benzinga Global Small Cap Conference

Wednesday, May 5, 2021 - 2:00pm

The Company\xe2\x80\x99s lead investigational product is the LOMECEL-B\xe2\x84\xa2 cell-based therapy product (\xe2\x80\x9cLomecel-B\xe2\x80\x9d), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors.

Key Points: 
  • The Company\xe2\x80\x99s lead investigational product is the LOMECEL-B\xe2\x84\xa2 cell-based therapy product (\xe2\x80\x9cLomecel-B\xe2\x80\x9d), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors.
  • Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders.
  • Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer\xe2\x80\x99s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS).
  • Further information relating to factors that may impact the Company\'s results and forward-looking statements are disclosed in the Company\'s filings with the SEC.

FDA Authorizes Novel Stem Cell Trial for Parkinson’s

Wednesday, April 28, 2021 - 12:00pm

b'Houston-area non-profit Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a Phase II double-blind placebo controlled clinical trial to assess the efficacy and safety of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells to improve activities of daily living and quality of life in subjects with Parkinson\xe2\x80\x99s Disease.\nThe trial is the first globally to administer pure adipose-derived mesenchymal stem cells to Parkinson\xe2\x80\x99s patients in such high quantities over repeat treatments.

Key Points: 
  • b'Houston-area non-profit Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a Phase II double-blind placebo controlled clinical trial to assess the efficacy and safety of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells to improve activities of daily living and quality of life in subjects with Parkinson\xe2\x80\x99s Disease.\nThe trial is the first globally to administer pure adipose-derived mesenchymal stem cells to Parkinson\xe2\x80\x99s patients in such high quantities over repeat treatments.
  • Twenty-four patients will be randomized to receive six intravenous infusions of 200 million stem cells each.\n\xe2\x80\x9cThis is our third FDA-authorized study for Parkinson\xe2\x80\x99s,\xe2\x80\x9d elaborates HBSCRF Founder Donna Chang.
  • From those, we gained an idea of what doses and periodicity of stem cell yielded dramatic results, and so were able to design this larger clinical trial very deliberately.
  • \xe2\x80\x9cWe have finally overcome the major hurdles of cell therapy.

Stem Cell Therapy Market worth $401 million by 2026 - Exclusive Report by MarketsandMarkets™

Wednesday, April 28, 2021 - 1:30pm

b'The Market growth is driven mainly by factors such as increasing investment in stem cell research and the rising number of GMP-certified stem cell manufacturing plants.

Key Points: 
  • b'The Market growth is driven mainly by factors such as increasing investment in stem cell research and the rising number of GMP-certified stem cell manufacturing plants.
  • However, factors such as ethical concerns and the high cost of stem cell research and manufacturing process likely to hinder the growth of this market.\nThe adipose tissue-derived MSCs segment accounted for the largest share of the cell source segment in the Stem Cell Therapy Market in 2020.\nBased on the cell source from which stem cells are obtained, the global market is segmented into four sources.
  • These include adipose tissue-derived MSCs (mesenchymal stem cells), bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources (which includes human corneal epithelium stem cells, peripheral arterial-derived stem cells, and induced pluripotent stem cell lines).
  • In 2020, adipose tissue-derived MSCs accounted for the markets largest share due to their increasing utilization in treating inflammatory diseases and wounds & injuries.